The Long-Term Risks of Afrezza Inhalation: What the Evidence Really Shows

For people with diabetes who require mealtime insulin, the daily routine of injections can be mentally and physically taxing. Afrezza (insulin human) inhalation powder, approved by the FDA in 2014, offers an alternative: a rapid-acting inhaled insulin delivered through a small, breath-powered device. It provides a needle-free option that mimics the body's natural prandial insulin spike, with peak levels reached in 12–15 minutes. Yet despite its appeal—particularly for those with needle phobia or injection-site complications—questions about its long-term safety have persisted. This article compiles current clinical evidence, expert opinions, and real-world monitoring data to help clinicians and patients make informed decisions about Afrezza's role in diabetes management.

Mechanism of Action and Pulmonary Dynamics

How Afrezza Enters the Bloodstream

Afrezza consists of a dry powder formulation of regular human insulin adsorbed onto Technosphere microparticles (fumaryl diketopiperazine). These particles are approximately 2–5 micrometers in diameter, a size engineered to deposit in the deep alveolar regions of the lungs rather than the upper airways. Once inhaled, the particles dissolve rapidly at the neutral pH of the alveolar lining fluid, releasing insulin into the pulmonary circulation. Because the alveolar epithelium is extremely thin and richly vascularized—about 0.1–0.5 µm thick—insulin passes into the bloodstream faster than it can from subcutaneous tissue.

Absorption, Peak, and Duration

Compared to rapid-acting injectable analogs (such as lispro or aspart), which require 30–90 minutes to peak, Afrezza reaches maximum serum concentration in 12–15 minutes and has a shorter duration of action (about 2.5–3 hours). This pharmacokinetic profile more closely approximates the physiological prandial insulin response, meaning the risk of late postprandial hypoglycemia—often seen with injectables—is reduced. However, the pulmonary route introduces variables that do not exist with subcutaneous injection: lung function variability, inhalation technique, and the potential for cumulative respiratory effects.

The Role of Technosphere Technology

The Technosphere carrier is not just a delivery vehicle. It is designed to be rapidly soluble and is cleared from the lungs by both dissolution and macrophage uptake. Preclinical studies have shown that Technosphere particles are phagocytosed by alveolar macrophages without triggering a strong inflammatory response. This property is critical because persistent particles in the lung can induce granuloma formation or fibrosis. Nonetheless, the long-term biological effect of repeated microparticle deposition in human lungs—over years or decades—remains an area of ongoing investigation.

Clinical Evidence Base for Afrezza Safety

Short‐Term Safety from Pivotal Trials

The pivotal Phase 3 trials (Affinity 1, 2, and 3) included over 2,500 patients with type 1 and type 2 diabetes exposed to Afrezza for at least 6 months. The most common adverse events were cough (approximately 25–30% of patients), throat pain, and minor wheezing. Most cases of cough were mild and tended to resolve within the first few weeks of therapy. Hypoglycemia rates were comparable to or slightly lower than those seen with injected rapid-acting insulin when administered in appropriate doses.

Spirometry data from these trials showed a small, early decline in forced expiratory volume in one second (FEV₁) during the first 3 months of use—typically a drop of 40–80 mL—followed by stabilization. This pattern suggests an acute bronchial response rather than progressive pulmonary damage. However, the trials were not designed to detect subtle changes that might emerge after several years of daily use.

Long‐Term Data and Knowledge Gaps

The longest controlled data available for Afrezza extend to about 104 weeks. A post-hoc analysis of pooled clinical trials published in Diabetes Technology & Therapeutics (2017) tracked lung function over two years and found no progressive decline beyond the initial minor drop. Yet experts note that 2 years is insufficient to rule out subclinical pulmonary remodeling. A 2021 review in Expert Opinion on Drug Safety concluded that “current long-term safety data are insufficient to exclude the possibility of chronic pulmonary fibrosis, loss of lung compliance, or increased susceptibility to infections after many years of use.”

Ongoing observational studies, such as the INHALE-2 registry (ClinicalTrials.gov identifier NCT03771664), are collecting real-world data over 5–10 years, but results are not yet available. This evidence gap is significant because many patients who start Afrezza may need insulin therapy for 30–50 years. Without robust long-term follow-up, clinicians must balance the known quality-of-life benefits against theoretical risks.

Expert Concerns Regarding Extended Use

Lung Function Decline and Parenchymal Changes

The central worry is whether chronic inhalation of insulin microparticles can cause irreversible lung damage. Animal models using high-dose, long-duration exposure have demonstrated focal inflammation and fibrosis in rodent lungs. However, human data at therapeutic doses have not replicated these findings. Despite this, guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend baseline spirometry and annual monitoring. A decline of more than 20% from baseline in FEV₁ should prompt immediate discontinuation and transition to injectable insulin.

Pulmonologists stress that even a small yearly decline in lung function—if cumulative—could become clinically meaningful after a decade. Dr. Mario Castro, a pulmonologist at the University of Kansas Medical Center, has stated: “We are advising patients that we need at least a decade of data before we can be fully confident about the absence of long-term lung toxicity. In the meantime, we only support Afrezza for individuals with normal baseline lung function and no history of lung disease, and we insist on strict spirometry reminders every six months.”

Respiratory Infections and Airway Inflammation

Observational reports and pooled trial data suggest a slightly higher rate of bronchitis and upper respiratory tract infections among Afrezza users. A 2022 meta-analysis of five randomized controlled trials found a non-significant trend toward more respiratory adverse events (risk ratio 1.12, 95% CI 0.96–1.30). This trend is not robust enough to implicate Afrezza as a cause of pneumonia, but it does raise the possibility that the inhaled insulin may alter local immune defenses or mucociliary clearance. Patients with active respiratory infections are advised to suspend Afrezza until symptoms resolve. Moreover, the inhaler device itself can harbor moisture and bacteria if not replaced monthly, so proper device hygiene is critical.

Cardiovascular Considerations

Although not a pulmonary risk, the rapid peak of inhaled insulin after inhalation may have cardiovascular implications. Theoretical concerns include transient hyperinsulinemia-induced sympathetic activation leading to arrhythmias or ischemia in susceptible patients. A dedicated cardiovascular safety trial (KATP) did not detect a signal for major adverse cardiac events over 12 months, but the sample size was moderate (approximately 800 patients) and excluded those with unstable heart disease. The FDA label explicitly states that Afrezza has not been studied in patients with unstable cardiac conditions, and clinicians should individualize risk assessment accordingly.

Theoretical Cancer Risk

Insulin is a known growth factor capable of binding to both insulin and insulin-like growth factor 1 (IGF-1) receptors. Chronic delivery of insulin directly to the lung epithelium could potentially stimulate cell proliferation. A 2018 review in Drug Design, Development and Therapy reported that no clinical evidence of increased lung cancer incidence has been observed in Afrezza trials to date. However, given the long latency period of lung cancer (often 10–20 years), current data cannot definitively exclude a small increased risk. Experts recommend that patients with a personal or strong family history of lung cancer approach Afrezza with caution, and that all patients be counseled on smoking cessation (smoking is an independent confounder).

Patient Populations at Higher Risk

Pre-Existing Lung Disease

Afrezza is contraindicated in patients with asthma and chronic obstructive pulmonary disease (COPD) because of the risk of acute bronchospasm and accelerated decline in lung function. Even patients with well-controlled asthma can experience a clinically significant drop in FEV₁. A retrospective analysis of patients with mild asthma who initiated Afrezza found an average 12% decline in FEV₁ within 3 months, compared to 4% in those without asthma. Any individual with abnormal baseline spirometry (FEV₁ less than 80% predicted or FEV₁/FVC ratio less than 0.70) should be offered alternative therapy unless a pulmonologist has cleared them after detailed evaluation.

Smokers and Vapers

Tobacco smoking acutely reduces insulin absorption from the lungs—likely due to altered airway geometry and increased mucus production—resulting in lower and more variable bioavailability of Afrezza. In addition, smoking is the strongest risk factor for many of the same long-term harms (lung cancer, emphysema, chronic bronchitis) that could be compounded by inhaled insulin. The FDA label advises against Afrezza use in current smokers. Vaping, while less studied, also introduces particles and toxins that may interact with the lung’s response to inhaled insulin. Most experts recommend that patients who start smoking or vaping while on Afrezza switch to injectable insulin and pursue smoking cessation resources.

Elderly and Pediatric Populations

The FDA has not approved Afrezza for patients under 18 years of age due to lack of safety and efficacy data. In elderly patients (≥65 years), natural age-related changes in lung function (reduced elastic recoil, decreased diffusion capacity) can be compounded by polypharmacy and other comorbidities. A pharmacokinetic study found that the area under the curve (AUC) and peak concentration (Cmax) were approximately 25% higher in older adults. The FDA label recommends starting at the lowest available dose (4 units) and titrating cautiously. No long-term lung safety data are available specific to the elderly, making spirometric surveillance even more crucial.

Mitigation Strategies and Monitoring Recommendations

Baseline and Periodic Pulmonary Function Testing

The ADA and EASD jointly recommend complete pulmonary function tests (PFTs) including FEV₁, forced vital capacity (FVC), total lung capacity (TLC), and diffusing capacity of the lungs for carbon monoxide (DLCO) before initiating Afrezza. These tests should be repeated at 6 and 12 months after starting therapy, and annually thereafter. Any reduction of 20% or greater in FEV₁ from baseline, or any new onset of dyspnea, wheeze, or cough, should lead to a prompt pulmonary reassessment and consideration of discontinuation. Many institutions have implemented protocols requiring annual pulmonology clearance for Afrezza patients.

Optimizing Inhaler Technique

Technique plays a major role in both tolerability and efficacy. Patients should be trained to insert the cartridge correctly, and to inhale slowly and deeply (not forcefully) from the device. After the breath, they should hold it for at least 15 seconds before exhaling to allow particles to settle in deep alveoli. Cough and throat irritation are often technique-related. Regular follow-up with a diabetes educator or respiratory therapist can help correct poor inhalation habits. In addition, the inhaler must be replaced every 30 days; it is not water washable and should be stored in a dry place to prevent microbial growth.

Infection Prevention and Seasonal Precautions

During influenza seasons or when patients develop symptoms of an upper respiratory infection (runny nose, sore throat, productive cough), a temporary suspension of Afrezza is prudent. Once symptoms resolve fully, therapy can be restarted. Patients with recurrent bronchitis should be evaluated for underlying lung disease before continuing Afrezza.

Balancing Benefits and Risks: A Clinical Decision Framework

Despite the uncertainties, many endocrinologists consider Afrezza a valuable tool for selected patients. Those with needle phobia, severe injection site lipodystrophy, or persistent postprandial hyperglycemia despite optimal injection therapy may experience meaningful improvements in glycemic control and quality of life. Dr. Anne Peters, director of the USC Westside Center for Diabetes, has remarked: “For the right patient, Afrezza is a game-changer. But it demands a disciplined approach to monitoring that not all patients can maintain.”

Conversely, pulmonologists often advocate for caution. The risk-benefit calculation should involve shared decision-making among the patient, the endocrinologist, and a pulmonologist. A practical algorithm might include:

  • Who is a candidate? Adults with type 1 or type 2 diabetes who require mealtime insulin, have normal baseline spirometry, no history of chronic lung disease, and are non-smokers.
  • Who should avoid or use with caution? Patients with FEV₁ <80% predicted, asthma/COPD, current smokers, those with strong family history of lung cancer, or those unable to adhere to annual spirometry.
  • Monitoring commitment: Patient must be willing to undergo PFTs every 6–12 months and to suspend therapy during respiratory infections.

Future Directions in Inhaled Insulin Research

New formulations and devices are under development. Researchers are exploring ultra-rapid insulins with modified particle size distributions to reduce upper airway deposition and improve tolerability. The inclusion of carrier excipients such as mannitol or trehalose may further mitigate local inflammation. Enrollment in long-term registries, such as the Inhaled Insulin Safety Study (ClinicalTrials.gov NCT03771664), is ongoing to collect real-world outcomes over 10 years. Additionally, studies are investigating biomarkers (e.g., surfactant protein D, Krebs von den Lungen-6) that could serve as early indicators of pulmonary change before spirometric decline.

Until such data mature, Afrezza remains a viable but not first-line option for mealtime insulin. Its advantages—rapid onset, needle-free delivery, improved postprandial glucose patterns—are clear. But the unknowns around long-term pulmonary safety require a framework of careful selection and vigilant monitoring.

Summary

Short-term data indicate that Afrezza is well tolerated by the majority of patients with normal lung function, with the principal risks being cough and a minor, self-limited dip in FEV₁. The long-term profile, however, is not fully characterized. Key concerns include possible progressive lung function decline, increased respiratory infections, and theoretical carcinogenic potential. High-risk groups—those with lung disease, smokers, the elderly, and children—should avoid Afrezza or be monitored extremely closely. With baseline and annual spirometry, attention to inhaler technique, and infection precautions, many patients can use Afrezza safely for years. However, until robust 10-year data emerge from registries and post-market surveillance, a cautious approach endorsed by lung specialist input is prudent.

For further reading, consult the FDA prescribing information for Afrezza, the American Diabetes Association Standards of Care, and the INHALE-2 registry trial. A comprehensive review of inhaled insulin safety published in Diabetes, Obesity and Metabolism (2020) also provides additional context.